STOCK TITAN

NEXGEL appoints Aviv Argaman to merger committee

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

NEXGEL, Inc. (NXGL) elected Aviv Argaman as an independent director effective November 12, 2026, and appointed him to a special committee on November 18. The committee, chaired by Steve Ciardiello and also including Jerome Zeldis, will evaluate and negotiate the proposed merger with Fountainhead LifeSciences and its affiliates and make recommendations to the board. NEXGEL has not entered into a definitive merger agreement.

Argaman founded and manages Asymmetry Point Capital LLC, the general partner and investment manager of Asymmetry Point LP. Asymmetry Point purchased $2.0 million aggregate principal amount of NEXGEL’s 2026 notes and elected a conditional conversion of 363,636 shares at $5.50 per share, plus approximately 5,868 shares for interest accrued through September 30, 2026. Conversion would occur only if the merger and other Conversion Closing conditions are met. The notes bear 10% interest; associated five-year warrants for 41,667 shares had their exercise price reduced from $16.00 to $13.00 and would be surrendered at Conversion Closing unless Asymmetry Point funds its full pro rata share of the New Capital Financing. Asymmetry Point did not participate in that financing.

Filing Explained

The filing identifies special-committee chair Steve Ciardiello as a noteholder whose notes would convert into common stock only if the proposed merger and other conversion conditions are met; this is conditional, not a completed share issuance.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Aggregate principal amount of notes $2.0 million Purchased by Asymmetry Point in NEXGEL’s 2026 private placements.
Note interest rate 10% Interest rate on the notes purchased by Asymmetry Point.
Existing Note Warrants 41,667 shares Warrants issued with the notes and held through Asymmetry Point.
Original warrant exercise price $16.00 per share Existing Note Warrants before the reduction under the Conversion Agreements.
Reduced warrant exercise price $13.00 per share Existing Note Warrants after the reduction under the Conversion Agreements.
Shares in elected note conversion 363,636 shares at $5.50 per share Conversion would occur only upon completion of the proposed merger and other Conversion Closing conditions.
Shares for accrued interest Approximately 5,868 shares Interest accrued through September 30, 2026; conversion is conditional on the merger and other Conversion Closing conditions.
private placement financial
"private placements of Notes in 2026"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
convertible promissory notes financial
"holders of its convertible promissory notes issued in 2026"
A convertible promissory note is a loan a company takes that can later be turned into shares instead of being paid back in cash; think of lending money now in exchange for a voucher that can become ownership later. Investors care because it mixes credit risk and potential ownership upside—it can protect lenders if a company struggles while also diluting existing shareholders when converted, affecting future share value and investor returns.
Conversion Closing financial
"at a closing (the “Conversion Closing”)"
registration rights financial
"and registration rights"
Registration rights are contractual promises that let investors require a company to file paperwork with securities regulators so those investors can sell their shares to the public. They matter because they create a path to liquidity and an exit plan—without them, investors may be stuck holding shares for a long time. Think of them like a reserved ticket that guarantees access to a public marketplace when the holder is ready to sell.
pro rata share financial
"funds its full pro rata share of the New Capital Financing"
Pro rata share is the portion of an asset, liability, income, loss, or new securities that an individual or entity receives based on their proportional ownership, contribution, or entitlement. It matters to investors because it determines how returns, dilution, distributions, or obligations are divided—think of slicing a pie so each person gets a piece sized exactly to the fraction of the whole they own.
forbearance financial
"consents, waivers, forbearance and voting agreement"
A temporary agreement between a borrower and lender to pause, reduce or delay loan payments when the borrower is facing financial difficulty. It matters to investors because forbearance changes expected cash flows and the risk of eventual default for loans or debt-backed assets—similar to a landlord agreeing to let a tenant skip rent for a few months; it can preserve value short-term but may signal elevated credit stress.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is on NXGL’s special committee?

The committee consists of Steve Ciardiello (chair), Jerome Zeldis, and Aviv Argaman and will evaluate and negotiate the proposed merger and make recommendations to the board.

How many NXGL shares did Asymmetry Point elect to receive from note conversion?

Asymmetry Point irrevocably elected to convert its notes into 363,636 shares at $5.50 per share, plus approximately 5,868 shares for interest accrued through September 30, 2026. The conversion is conditioned on completion of the proposed merger and other Conversion Closing conditions.

What happens to Asymmetry Point’s NXGL note warrants?

At Conversion Closing, the warrants would be surrendered unless Asymmetry Point funds its full pro rata share of the New Capital Financing. Asymmetry Point did not participate in that financing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001468929 0001468929 2026-11-12 2026-11-12 0001468929 NXGL:CommonStockParValue0.001Member 2026-11-12 2026-11-12 0001468929 NXGL:WarrantsToPurchaseCommonStockMember 2026-11-12 2026-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 12, 2026

 

NEXGEL, INC.
(Exact name of registrant as specified in its charter)

 

Delaware   001-41173   26-4042544

(State or other jurisdiction

of incorporation)

  (Commission
File Number)
 

(IRS Employer

Identification No.)

 

2150 Cabot Boulevard West, Suite B

Langhorne, Pennsylvania

  19047
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (215) 702-8550

 

(Former name or former address, if changed since last report)

Not Applicable

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001   NXGL   The Nasdaq Capital Market LLC
Warrants to Purchase Common Stock   NXGLW   The Nasdaq Capital Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On November 12, 2026, the Board of Directors (the “Board”) of NexGel, Inc.,, a Delaware company (the “Company”), elected Aviv Argaman as a director, effective immediately, to serve until the Company’s next annual meeting of stockholders and until his successor is elected and qualified. The Board has determined that Mr. Argaman is an independent director under the Nasdaq Listing Rules. On November 18, 2026, the Board also appointed Mr. Argaman to the special committee of the Board described in Item 8.01. There is no arrangement or understanding between Mr. Argaman and any other person under which he was selected as a director, and there are no family relationships between Mr. Argaman and any director or executive officer of the Company.

 

Mr. Argaman, age 36, has been a full-time professional investor since 2021. Since 2024, he has been the founder and manager of Asymmetry Point Capital LLC, an investment firm that serves as the general partner and investment manager of Asymmetry Point LP, a Delaware limited partnership (“Asymmetry Point”), and its feeder fund, Asymmetry Point CF I. From 2022 to 2024, he founded and managed Asymmetry Point Capital Ltd., an Israeli investment firm. Before 2021, he worked in engineering and management consulting. He holds a double B.Sc. in Electrical Engineering and Physics from the Technion, Israel Institute of Technology.

 

As previously reported in the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on November 12, 2026 (the “Prior Form 8-K”), on November 10, 2026, the Company entered into a Securities Purchase Agreement for a private placement (the “New Capital Financing”) of its common stock, par value $0.001 per share (“Common Stock”), and warrants. On the same date, the Company entered into Note Amendment and Conversion Agreements (the “Conversion Agreements”) with holders (the “Holders”) of its convertible promissory notes issued in 2026 (the “Notes”). Under the Conversion Agreements, the Notes will convert into Common Stock at a closing (the “Conversion Closing”) that will occur only upon, and subject to, the completion of a proposed business combination between the Company and Fountainhead LifeSciences and its affiliates, including Sequence LifeScience, Inc. and NVISION Biomedical Technologies, Inc. (the “Merger”), and the other conditions described in the Prior Form 8-K. The Company has not entered into a definitive agreement for the Merger. Share and per-share amounts in this report give effect to the 1-for-20 reverse stock split effective October 12, 2026.

 

Mr. Argaman has an indirect interest, through Asymmetry Point, in the following transactions with the Company since January 1, 2025. Asymmetry Point purchased $2.0 million aggregate principal amount of the Notes in the Company’s private placements of Notes in 2026 (issued on April 17, 2026 and July 2, 2026), on the same terms as the other investors, including 10% interest, five-year warrants issued with the Notes (the “Existing Note Warrants”) exercisable for 41,667 shares of Common Stock at an exercise price of $16.00 per share, and registration rights.

 

Asymmetry Point is a Holder and a party to one of the Conversion Agreements, on the same terms as the other Holders. Under it, Asymmetry Point irrevocably elected to convert its Notes into 363,636 shares of Common Stock at $5.50 per share and to receive approximately 5,868 shares of Common Stock for interest accrued through September 30, 2026, in each case only upon completion of the Merger and the other conditions to the Conversion Closing described in the Prior Form 8-K. The exercise price of its Existing Note Warrants was reduced to $13.00 per share, and the warrants will be surrendered at the Conversion Closing unless Asymmetry Point funds its full pro rata share of the New Capital Financing. Asymmetry Point also gave the consents, waivers, forbearance and voting agreement described in the Prior Form 8-K. Asymmetry Point did not participate in the New Capital Financing.

 

Mr. Argaman will receive the Company’s standard non-employee director compensation, which has not yet been determined.

 

Item 8.01. Other Events.

 

On November 18, 2026, the Board established a special committee of independent directors (the “Special Committee”) consisting of Steve Ciardiello (Chair), Jerome Zeldis and Aviv Argaman, to evaluate and negotiate the proposed Merger and make recommendations to the Board, with customary authority to retain independent legal and financial advisors. The Board has determined that each member of the Special Committee is independent under the Nasdaq Listing Rules. Each member of the Special Committee other than Mr. Zeldis holds Notes (in the case of Mr. Argaman, through Asymmetry Point, as described in Item 5.02), which would automatically convert into Common Stock if the Merger is completed, as described in the Prior Form 8-K.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 18, 2026    
     
  NEXGEL, INC.
     
  By: /s/ Brian Kieser
   

Brian Kieser

Interim Chief Executive Officer

 

 

 

Filing Exhibits & Attachments

4 documents

Keep reading